GeneReach Biotechnology Cash Flow-to-Debt Ratio
GeneReach Biotechnology cash flow-to-debt ratio. GeneReach Biotechnology (4171) has a Cash Flow-to-Debt Ratio of 0.02x as of June 2026, meaning its operating cash flow of NT$6.28 Million could theoretically repay 0% of its total liabilities (NT$276.64 Million) in one year. Check GeneReach Biotechnology cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of GeneReach Biotechnology (2017–2025)
Cash flow-to-debt ratio of GeneReach Biotechnology from 2017 to 2025. Historical debt coverage capacity for GeneReach Biotechnology across 9 annual periods. Check GeneReach Biotechnology cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
GeneReach Biotechnology Cash Flow-to-Debt Ratio by Year (2017–2025)
GeneReach Biotechnology cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for GeneReach Biotechnology. For the full cash flow conversion analysis, see 4171 cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.05x | NT$-13.52 Million | NT$284.34 Million | ▲ +30.2% |
| 2024 | -0.07x | NT$-23.22 Million | NT$341.00 Million | ▲ +44.8% |
| 2023 | -0.12x | NT$-38.67 Million | NT$313.71 Million | ▼ -117.9% |
| 2022 | 0.69x | NT$357.63 Million | NT$519.23 Million | ▲ +17.7% |
| 2021 | 0.59x | NT$348.99 Million | NT$596.35 Million | ▲ +31.9% |
| 2020 | 0.44x | NT$169.82 Million | NT$382.75 Million | ▲ +765.2% |
| 2019 | -0.07x | NT$-11.19 Million | NT$167.82 Million | ▼ -544.4% |
| 2018 | 0.02x | NT$5.74 Million | NT$382.68 Million | ▲ +177.4% |
| 2017 | -0.02x | NT$-6.83 Million | NT$352.21 Million | — |